- Home
- TDUP vs LXEO Comparison
TDUP vs LXEO Comparison
Compare TDUP & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TDUP | LXEO |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 750.9M | 731.3M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TDUP | LXEO |
|---|---|---|
| Price | $4.52 | $6.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $12.50 | ★ $18.60 |
| AVG Volume (30 Days) | ★ 1.8M | 864.9K |
| Earning Date | 03-02-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $298,376,000.00 | N/A |
| Revenue This Year | $20.94 | N/A |
| Revenue Next Year | $11.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 41.65 | N/A |
| 52 Week Low | $2.02 | $1.45 |
| 52 Week High | $12.28 | $10.99 |
Technical Indicators
Market Signals| Indicator | TDUP | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 35.59 | 28.97 |
| Support Level | $4.46 | $6.73 |
| Resistance Level | $4.83 | $7.31 |
| Average True Range (ATR) | 0.31 | 0.47 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 11.65 | 1.37 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.